Abstract 204P
Background
Exploring the interaction between tissue and circulating immune descriptors may represent a critical step in our understanding of cancer immunity cycle to dissect distinct immunotherapy (IO) outcomes. Thus, we determined whether a comprehensive immune profiling, including tumor immune microenviroment (TIME) and peripheral blood (PB) might offer an “holistic” view of patient-specific immune background, potentially leading to new personalized therapeutic strategies.
Methods
On 59 consecutive IO-treated NSCLC patients, digital microscopy was employed on tissue samples to assess densities and spatial distribution (intratumor and stromal) of different Tumor-infiltrating lymphocytes (TILs) subpopulations (CD3+, CD4+-CD8+, PD-1+); peripheral blood (PB) samples were analyzed by Flow cytometry and immunenzymatic assay to determine circulating immune-inflammatory features. Statistical analyses were conducted to assess potential correlations between TIME and blood immune features.
Results
In our cohort of NSCLC patients, PB analysis revealed a significant direct correlation between the density of total and intratumor CD3+ TILs and the percentage of circulating CD3+ T cells. Moreover, higher CD8+ TILs correlated with an increase in circulating CD8+Ki67+ and a decrease in immunosuppressive Tregs (P<0.05). Cytokine analysis showed that IL-6 direclty correlated with TILs density, while IL-1β, IL-12p70, and IL-2 were linked to CD8/CD3 ratios (P<0.05). An inverse relationship was observed between PD-1/CD8 ratio and IL-1β, IFN-γ and TGF-β1, along with a negative correlation between IL-4 and PD-1+ TILs (P<0.05). Additionally, we found that PD-L1neg patients displayed higher levels of blood monocytes and Tregs. Increased PD-L1 expression correlated with higher CD3+ TILs, and a significant inverse relationship was noted between PD-L1 levels and the PD1-to-CD8 TILs ratio, suggesting that PD-L1+ cancer cells may inhibit cytotoxic T cells.
Conclusions
Our findings strongly suggest the existence of a complex crosstalk between tissue and circulating compartments in shaping the immune response against the tumor and likely the proneness to benefit from immunotherapy in advanced NSCLC patients.
Legal entity responsible for the study
University Hospital of Parma.
Funding
AIRC Associazione Italiana Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract